CMS proposes delaying certain Medicaid value-based drug payment requirements

The Centers for Medicare & Medicaid Services yesterday proposed delaying Medicaid “best price” and “best price reporting” requirements for state value-based purchasing agreements with drug manufacturers until July 2022. The six-month delay also would apply to a requirement that drug makers include drugs sold in U.S. territories when calculating the best price. The requirements were included in a December 2020 CMS final rule on value-based drug payment. CMS will accept comments on the proposed rule through June 28. The Pharmaceutical Research and Manufacturers of America last week challenged portions of the final rule in federal court.